Published in Front Oncol on September 29, 2014
GEN3VA: aggregation and analysis of gene expression signatures from related studies. BMC Bioinformatics (2016) 0.78
Association between EPHX1 rs1051740 and lung cancer susceptibility: a meta-analysis. Int J Clin Exp Med (2015) 0.75
Gene set selection via LASSO penalized regression (SLPR). Nucleic Acids Res (2017) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res (2000) 117.00
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (2004) 32.08
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Using GOstats to test gene lists for GO term association. Bioinformatics (2006) 12.58
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 11.68
A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics (2008) 6.45
Assessment and comparison of prognostic classification schemes for survival data. Stat Med (1999) 5.94
A comprehensive evaluation of multicategory classification methods for microarray gene expression cancer diagnosis. Bioinformatics (2004) 4.70
Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One (2010) 3.96
RB and cell cycle progression. Oncogene (2006) 3.77
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol (2004) 3.47
FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science (2010) 2.80
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol (2013) 2.41
IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett (2009) 2.35
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol (2013) 2.25
p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol (2011) 2.24
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med (2008) 1.94
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther (2006) 1.88
The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol (2012) 1.82
Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol (2011) 1.78
Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 1.77
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst (2008) 1.71
Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci U S A (2004) 1.67
Identification of a colon mucosa gene that is down-regulated in colon adenomas and adenocarcinomas. Proc Natl Acad Sci U S A (1993) 1.58
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol (2009) 1.44
Filamins regulate cell spreading and initiation of cell migration. PLoS One (2009) 1.36
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol (2009) 1.35
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res (2011) 1.35
Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med (2010) 1.34
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol (2009) 1.30
Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res (2007) 1.26
OrderedList--a bioconductor package for detecting similarity in ordered gene lists. Bioinformatics (2006) 1.25
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One (2013) 1.22
Mechanical influences on vascular smooth muscle cell function. J Hypertens (1998) 1.15
Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res (2001) 1.14
Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res (2012) 1.09
Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: a review and update. Appl Immunohistochem Mol Morphol (2012) 1.09
Conserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarrays. Nucleic Acids Res (2005) 1.07
Building models using Reactome pathways as templates. Methods Mol Biol (2013) 1.07
Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol (1999) 1.04
Integrin-linked kinase controls vascular wall formation by negatively regulating Rho/ROCK-mediated vascular smooth muscle cell contraction. Genes Dev (2009) 1.01
Microtubules and actin crosstalk in cell migration and division. Cytoskeleton (Hoboken) (2013) 1.00
Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res (2009) 0.99
Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol (2010) 0.98
Autophagy plays a critical role in the degradation of active RHOA, the control of cell cytokinesis, and genomic stability. Cancer Res (2013) 0.97
Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One (2009) 0.96
The role of cyclin D1 expression and patient's survival in non-small-cell lung cancer: a systematic review with meta-analysis. Clin Lung Cancer (2011) 0.96
ExpressionBlast: mining large, unstructured expression databases. Nat Methods (2013) 0.96
Structure-based variable selection for survival data. Bioinformatics (2010) 0.95
Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis. PLoS One (2013) 0.94
Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer (2010) 0.94
Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients. PLoS One (2012) 0.93
Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer Study. Am J Clin Pathol (2013) 0.93
Roles of testicular orphan nuclear receptors 2 and 4 in early embryonic development and embryonic stem cells. Endocrinology (2009) 0.92
IQGAP2, A candidate tumour suppressor of prostate tumorigenesis. Biochim Biophys Acta (2012) 0.88
Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol Ther (2006) 0.87
Hypomethylation of the 14-3-3σ promoter leads to increased expression in non-small cell lung cancer. Genes Chromosomes Cancer (2011) 0.87
A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer (2008) 0.86
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Ann Oncol (2011) 0.86
Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res (2005) 0.85
Pathway databases: making chemical and biological sense of the genomic data flood. Chem Biol (2013) 0.83
Down-regulation of the down-regulated in adenoma (DRA) gene correlates with colon tumor progression. Clin Cancer Res (1998) 0.83
Genetic network and gene set enrichment analysis to identify biomarkers related to cigarette smoking and lung cancer. Cancer Treat Rev (2012) 0.83
Improving patient management in metastatic non-small cell lung cancer. Lung Cancer (2007) 0.82
Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res (2011) 0.82
An exploration of pathways involved in lung carcinoid progression using gene expression profiling. Carcinogenesis (2013) 0.81
Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma. PLoS One (2012) 0.80
Thyroid transcription factor-1 is not expressed in squamous cell carcinomas of the lung: an immunohistochemical study with review of the literature. Appl Immunohistochem Mol Morphol (2012) 0.79
Chemotherapy: continued lack of progress in SCLC. Nat Rev Clin Oncol (2010) 0.77
Immunohistochemistry of cyclin D3 in pulmonary carcinomas. Virchows Arch (1996) 0.76